A growing body of evidence

Key clinical outcomes support the use of the FreeStyle Libre portfolio across treatment regimens^*†1-15

see HbA1c outcomes

Children playing with Mom wearing FreeStyle LIbre 3 sensor on her arm

Improved outcomes

In studies, the FreeStyle Libre portfolio use/acquisition was associated with:

Lowered
HbA1c^{*†1-4,9-11,13}

Reduced resource utilization^{*†4,5,8,12,14,15}

Reduced number of hypoglycemic events^*†6,7

Reduced work absenteeism^*†4,8

Reduced HbA1c^{*†1-4,9-11,13}

Use of the FreeStyle Libre portfolio was associated with lower HbA1c across the diabetes spectrum^{*†3,9,10,13}.

↓0.4%^*†3

Children^*†3

P<0.0001

↓0.4%^*†9

T1D^*†9

P<0.0001

↓0.9%^*†10

T2D MDI^*†10

P<0.0001

↓1.1%^*†13

T2D Basal-only insulin users^*†13

P<0.0001

↓1.6%^*†13

T2D Non-insulin users^*†13

P<0.0001

Meta-analysis (T1D and T2D)^*†‡2

75 studies

0.42%

reduction in HbA1c for people with T1D (at 4.5-7.5 months)

0.59%

reduction in HbA1c for people with T2D (at 4.5-7.5 months)

30,478

participants

SEE STUDY SUMMARIES

Reduced resource utilization (after purchase)^{*†4,5,8,12,14,15}

Acquisition of the FreeStyle Libre portfolio is associated with reductions in diabetes-related resource utilization.

66%

reduction in diabetes-related hospital admissions in T1D/T2D^*†§4

[187 (13.7%) to 32 (4.7%) at 12 months; P<0.05]

61%

reduction in acute diabetes events in T2D on intensive insulin regimens^*†||5

P<0.001

SEE STUDY SUMMARIES

Reduced number of hypoglycemic events^*†6,7

FreeStyle Libre portfolio users had significant reduction in hypoglycemic events^*†6,7.

41%

reduction in number
of hypoglycemic
events for T1D^*†6

[<55 mg/dL; −0.38/24-h day; P<0.0001]

44%

reduction in number
of hypoglycemic
events for T2D^*†7

[<55 mg/dL; −0.12/24-h day; P=0.0017]

SEE STUDY SUMMARIES

Reduced work absenteeism^*†¶4,8

Acquisition of the FreeStyle Libre portfolio was associated with reductions in work absenteeism^*†¶4,8.

58%

reduction in work absenteeism among patients with T1D/T2D^*†¶4

[18.5% to 7.7%; P<0.05]

50%

reduction in absenteeism among patients with T1D^*†¶8

[5.8% to 2.9%; P<0.0001]

SEE STUDY SUMMARIES

The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.

The FreeStyle Libre 2 system and FreeStyle Libre 3 system are indicated for patients ages 4 and older.

* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
‡ A meta-analysis of RCTs and single arm studies (in addition to real world observational studies) on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c.
§ Represents percentage of people experiencing a diabetes-related hospital admission.
|| Represents inpatient events or emergency outpatient events for hypoglycemia, hyperglycemia, diabetic ketoacidosis, or hyperosmolarity.
¶ Represents percentage of patients reporting work absenteeism.

References: 1. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166 2. Evans M, et al. Diabetes Therapy (2022): https://doi.org/10.1007/s13300-022-01253-9 3. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 4. Fokkert, M. BMJ Open Diabetes Res & Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 5. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 6. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 7. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 8. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 9. Tyndall, V. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 10. Kroger, J. Diabetes Ther (2020): https://doi.org/10.1007/s13300-019-00741-9 11. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 12. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 13. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 14. Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts 15. Deshmukh, H. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738

ADC-17131 v6.0 06/22

A growing body of evidence

Improved outcomes

In studies, the FreeStyle Libre portfolio use/acquisition was associated with:

Lowered HbA1c*†1-4,9-11,13

Reduced resource utilization*†4,5,8,12,14,15

Reduced number of hypoglycemic events*†6,7

Reduced work absenteeism*†4,8

Reduced HbA1c*†1-4,9-11,13

Use of the FreeStyle Libre portfolio was associated with lower HbA1c across the diabetes spectrum*†3,9,10,13.

↓0.4%*†3

Children*†3

↓0.4%*†9

T1D*†9

↓0.9%*†10

T2D MDI*†10

↓1.1%*†13

T2D Basal-only insulin users*†13

↓1.6%*†13

T2D Non-insulin users*†13

Meta-analysis (T1D and T2D)*†‡2

75

studies

0.42%

reduction in HbA1c for people with T1D (at 4.5-7.5 months)

0.59%

reduction in HbA1c for people with T2D (at 4.5-7.5 months)

30,478

participants

Reduced resource utilization (after purchase)*†4,5,8,12,14,15

Acquisition of the FreeStyle Libre portfolio is associated with reductions in diabetes-related resource utilization.

66%

reduction in diabetes-related hospital admissions in T1D/T2D*†§4

61%

reduction in acute diabetes events in T2D on intensive insulin regimens*†||5

Reduced number of hypoglycemic events*†6,7

FreeStyle Libre portfolio users had significant reduction in hypoglycemic events*†6,7.

41%

reduction in number of hypoglycemic events for T1D*†6

44%

reduction in number of hypoglycemic events for T2D*†7

Reduced work absenteeism*†¶4,8

Acquisition of the FreeStyle Libre portfolio was associated with reductions in work absenteeism*†¶4,8.

58%

reduction in work absenteeism among patients with T1D/T2D*†¶4

50%

reduction in absenteeism among patients with T1D*†¶8

SITE PAGES

Other Freestyle Libre Sites

Stay connected

Disclaimer

Lowered
HbA1c^{*†1-4,9-11,13}

Reduced resource utilization^{*†4,5,8,12,14,15}

Reduced number of hypoglycemic events^*†6,7

Reduced work absenteeism^*†4,8

Reduced HbA1c^{*†1-4,9-11,13}

Use of the FreeStyle Libre portfolio was associated with lower HbA1c across the diabetes spectrum^{*†3,9,10,13}.

↓0.4%^*†3

Children^*†3

↓0.4%^*†9

T1D^*†9

↓0.9%^*†10

T2D MDI^*†10

↓1.1%^*†13

T2D Basal-only insulin users^*†13

↓1.6%^*†13

T2D Non-insulin users^*†13

Meta-analysis (T1D and T2D)^*†‡2

Reduced resource utilization (after purchase)^{*†4,5,8,12,14,15}

reduction in diabetes-related hospital admissions in T1D/T2D^*†§4

reduction in acute diabetes events in T2D on intensive insulin regimens^*†||5

Reduced number of hypoglycemic events^*†6,7

FreeStyle Libre portfolio users had significant reduction in hypoglycemic events^*†6,7.

reduction in number
of hypoglycemic
events for T1D^*†6

reduction in number
of hypoglycemic
events for T2D^*†7

Reduced work absenteeism^*†¶4,8

Acquisition of the FreeStyle Libre portfolio was associated with reductions in work absenteeism^*†¶4,8.

reduction in work absenteeism among patients with T1D/T2D^*†¶4

reduction in absenteeism among patients with T1D^*†¶8